What's new? Log in Free sign up

Xeris Pharmaceuticals

Company Profile

Company profile

Website

www.xerispharma.com

CEO

paul Edick

Incorporated

Location

Fiscal year end

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co. • Alabama Power • Mississippi Power • Teva Pharmaceutical Industries Limited • Entergy Arkansas • Abbott Laboratories • Eli Lilly and • Bristol-Myers Squibb ...

SEC CIK

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Material Contracts & Credit Agreements

Latest filings (excl ownership)

View all

Securities registration termination

Notice of effectiveness

Exchange delisting

Prospectus update (post-effective amendment)

Registration of securities for employees (post-effective amendment)

Registration of securities for employees (post-effective amendment)

Registration of securities for employees (post-effective amendment)

Registration of securities for employees (post-effective amendment)

Completion of Acquisition or Disposition of Assets

Entry into a Material Definitive Agreement

Transcripts

View all

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Latest ownership filings

View all

Sessa Capital (Master), L.P.

BARBARA-JEAN ANNE BORMANN-KENNEDY

JEFFREY W SHERMAN

STEVEN PRESTRELSKI

KENNETH ERLAND JOHNSON

Financial summary

Financial statements Chart financial data

Quarter (USD)	Jun 21	Mar 21	Dec 20	Sep 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 20	Dec 19	Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	63.60 mm	63.60 mm	63.60 mm	63.60 mm	63.60 mm	63.60 mm
Cash burn (monthly)	1.00 mm	3.24 mm	8.60 mm	6.30 mm	6.67 mm	5.99 mm
Cash used (since last report)	41.89 mm	135.44 mm	359.46 mm	263.51 mm	279.10 mm	250.33 mm
Cash remaining	21.71 mm	-71.84 mm	-295.86 mm	-199.91 mm	-215.50 mm	-186.73 mm
Runway (months of cash)	21.7	-22.2	-34.4	-31.7	-32.3	-31.2

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q2 2024

Xeris Pharmaceuticals institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	80	128	-37.5%
Opened positions	24	46	-47.8%
Closed positions	72	17	+323.5%
Increased positions	24	35	-31.4%
Reduced positions	16	24	-33.3%

13F shares	Current	Prev Q	Change
Total value	51.01 bn	99.95 bn	-49.0%
Total shares	33.65 mm	57.60 mm	-41.6%
Total puts	45.00 k	0.00	NEW
Total calls	126.30 k	21.90 k	+476.7%
Total put/call ratio	0.4	–	–

Largest owners	Shares	Value	Change
Flynn James E	5.88 mm	$17.24 mm	0.0%
MPM Oncology Impact Management	4.83 mm	$10.87 bn	NEW
Sessa Capital	3.26 mm	$0.00	0.0%
STT State Street	3.26 mm	$7.33 bn	+1.4%
Rosalind Advisors	3.12 mm	$7.02 bn	+10.6%
Millennium Management	1.70 mm	$3.82 bn	NEW
MS Morgan Stanley	1.61 mm	$3.62 bn	+24.7%
Aqr Capital Management	1.19 mm	$2.68 bn	NEW
Redmile	1.05 mm	$2.35 bn	NEW
BAC Bank of America	641.67 k	$1.44 bn	NEW

Largest transactions	Shares	Bought/sold	Change
BLK BlackRock	0.00	-9.96 mm	EXIT
Vanguard	0.00	-7.61 mm	EXIT
Caxton	0.00	-5.11 mm	EXIT
MPM Oncology Impact Management	4.83 mm	+4.83 mm	NEW
Geode Capital Management	0.00	-3.05 mm	EXIT
Millennium Management	1.70 mm	+1.70 mm	NEW
Nuveen Asset Management	0.00	-1.59 mm	EXIT
CenterBook Partners	0.00	-1.54 mm	EXIT
Aqr Capital Management	1.19 mm	+1.19 mm	NEW
NTRS Northern Trust	0.00	-1.16 mm	EXIT

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.